What chemotherapy regimens are used for Triple-Negative Breast Cancer

Chemotherapy Regimens for Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is treated differently than other breast cancers because it lacks estrogen receptors (ER-), progesterone receptors (PR-), and HER2 receptors (HER2-). This means hormone therapy and HER2-targeted drugs won't work, so chemotherapy is the primary systemic treatment option.

Standard Chemotherapy Regimens

According to NCCN Guidelines, the preferred chemotherapy combinations for TNBC include:

Preferred Regimens:

1. AC followed by Paclitaxel

   • AC = Doxorubicin + Cyclophosphamide
   • Followed by Paclitaxel (a taxane drug)
   • This is a sequential approach given over several months

2. TC (Docetaxel + Cyclophosphamide)

   • An alternative to the AC regimen
   • May be preferred for some patients

3. Carboplatin-based combinations

   • Carboplatin + Paclitaxel
   • Carboplatin + Docetaxel
   • These are particularly useful in TNBC because platinum drugs work well against triple-negative tumors

Enhanced Treatment Approaches

Immunotherapy Addition (Pembrolizumab)

For patients receiving preoperative (neoadjuvant) therapy before surgery, NCCN Guidelines recommend:

• Pembrolizumab (an immunotherapy drug) combined with:
  • Carboplatin + Paclitaxel, followed by
  • Pembrolizumab + Cyclophosphamide with Doxorubicin or Epirubicin, followed by
  • Adjuvant (after-surgery) Pembrolizumab

This approach has shown improved outcomes in TNBC patients.

BRCA Mutation Consideration

If you have a germline BRCA1 or BRCA2 mutation, NCCN Guidelines indicate that Olaparib (a PARP inhibitor) may be used as adjuvant therapy after chemotherapy. PARP inhibitors work particularly well in BRCA-mutated cancers.

Capecitabine for Residual Disease

If cancer remains after preoperative chemotherapy with taxanes, alkylators, and anthracyclines, NCCN Guidelines recommend considering Capecitabine as additional therapy.

Important Treatment Considerations

Timing matters: Chemotherapy is typically given either:

• Before surgery (neoadjuvant) to shrink the tumor first, OR
• After surgery (adjuvant) to eliminate remaining cancer cells

Side effect management is important:

• Peripheral neuropathy (nerve damage in hands/feet) from taxanes can be reduced with cryotherapy (cooling hands and feet during treatment)
• Hair loss may be reduced with scalp cooling
• Cardiac monitoring is needed with anthracycline drugs like doxorubicin

Questions to Ask Your Oncologist

1. Which chemotherapy regimen do you recommend for my specific case, and why?
2. Will I receive chemotherapy before or after surgery?
3. Do I have a BRCA mutation, and if so, does that change my treatment plan?
4. What side effects should I expect, and how will we manage them?
5. Will immunotherapy (pembrolizumab) be part of my treatment?
6. How will we monitor my response to treatment?

---

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.